No Detail Found!

Efficacy and tolerability of tegaserod in constipation dominant irritable bowel syndrome.

Author(s)
S. H. A. Shah Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan
S. W. Jafri Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan
M. Gul Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan
A. Mohsin Mayo Haspital, Lahore, Pakistan
M. N. Afzal Mayo Haspital, Lahore, Pakistan
J. A. Butt Pakistan Institute of Medical Sciences (PIMS), Islamabad, Pakistan
I. Khan Hayatabad Medical Complex, Peshawar, Pakistan
A. Naqvi Novartis Pharma Pakistan Ltde. Pakistan
I. Rasheed Novartis Pharma Pakistan Ltde. Pakistan
Abstract
To determine the efficacy and tolerability of tegaserod in the treatment of symptoms of irritable bowel syndrome (IBS) IBS-C patients. An open label (quasi interventional) study. Patients were enrolled between October 2000 and August 2001 at 4 centres (AKUH, Karachi; Mayo Hospital, Lahore; PIMS, Islamabad; Hayatabad Teaching Complex, Peshawar). Tegaserod was administered in a dose of 6 mg (twice-a-day) orally for a period of 6 weeks. Symp­toms were assessed before and during treatment using a questionnaire. The mean age of patients was 37.5 years and 81(69.2%) were males. The study enrolled 117 patients and 101 patients completed the study. Number of bowel movements, symptoms of straining at defecation, stool consistency, bloat­ing, urgency and abdominal pain improved significantly following treatment (p
Publication Details
Page(s) 21-24
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 14, Issue: 1, Year: 2004

Request the full text from PASTIC

0

Citations

0

Downloads

164

Views